EB_spring_2018_Rutger_Oudejans.jpg

Rutger Oudejans, Brand Director at bioLIVE, postulates that the bio supply chain could learn some lessons from the small molecules sector. The bio industry continues to expand at rates above the traditional NCE (New Chemical Entity) sector, yet for the supply chain there are vital synergies that could help further accelerate developments.

CAR T cells attacking cancer. 
© Prasad S. Adusumilli, MD, FACS/Memorial Sloan Kettering Cancer Center

French allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis. 

csm_carsten-thiel_f88a4077c6.jpg

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.

Staphylococcus aureus F98Y DHFR complexed with iclaprim © http://www.ebi.ac.uk/pdbe/entry/pdb/3FR

Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients. 

tk_11_2017_ute_kilger_16x9.jpg

Is cheaper always better when it comes to generics? What about when it comes to innovative medical uses of them?